Infectious Complications of Implantable Venous Access Devices in Patients with Sickle Cell Disease

Journal of Vascular and Interventional Radiology

Volumn 15, Issue 4, 2004, Pages 375-378

  Wagner, Steven C ^a   Eschelman, David J ^a   Gonsalves, Carin F ^a   Bonn, Joseph ^a   Sullivan, Kevin L ^b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; CATHETER; CATHETER INFECTION; CAUSE OF DEATH; CLINICAL ARTICLE; DEVICE INFECTION; DEVICE REMOVAL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SICKLE CELL ANEMIA; STAPHYLOCOCCUS AUREUS; VASCULAR ACCESS; WOUND;

EID: 1842557968     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000121410.46920.6E     Document Type: Article

References (17)

1. Foley MJ. Radiologic placement of long-term central venous Peripheral Access System Ports (PAS Port): results in 150 patients. J Vasc Interv Radiol 1995; 6:255-262.
2. Hills JR, Cardella JF, Cardella K, Waybill PN. Experience with 100 consecutive central venous access arm ports placed by interventional radiologists. J Vasc Interv Radiol 1997; 8:983-989.
3. Denny DF. Placement and management of long-term central venous access catheters and ports. AJR Am J Roentgenol 1993; 161:385-393.
4. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. MMWR Recomm Rep 2002; 51:1-28.
5. McCready CE, Doughty HA, Pearson TC. Experience with the Port-A-Cath in sickle cell disease. Clin Lab Haem 1996; 18:79-82.
6. Phillips G, Slingluff C, Hartman J, Thomas P, Akwari O. Totally implantable intravenous catheters in the management of sickle cell anemia. Am J Hematol 1988; 29:134-138.
7. Sotir MJ, Lewis C, Bisher EW, Ray SM, Soucie JM, Blumberg HM. Epidemiology of device-associated infections related to a long-term implantable vascular access device. Infect Control Hosp Epidemiol 1999; 20:187-191.
8. Jeng MR, Feusner J, Skibola C, Vichinsky E. Central venous catheter complications in sickle cell disease. Am J Hematol 2002; 69:103-108.
9. Groeger JS, Lucas AB, Thaler HT, et al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993; 119:1168-1174.
10. Kaufman JA, Salamipour H, Geller SC, Rivitz SM, Waltman AC. Long-term outcomes of radiologically placed arm ports. Radiology 1996; 201:725-730.
11. Di Carlo I, Cordio S, La Greca G, et al. Totally implantable venous access devices implanted surgically. Arch Surg 2001; 136:1050-1053.
12. Grannan KJ, Taylor PH. Early and late complications of totally implantable venous access devices. J Surg Oncol 1990; 44:52-54.
13. Torramade JR, Cienfuegos JA, Hernandez JL, et al. The complications of central venous access systems: a study of 218 patients. Eur J Surg 1993; 159: 323-327.
14. Whigham CJ, Goodman CJ, Fisher RG, Greenbaum MC, Thornby JI, Thomas JW. Infectious complications of 393 peripherally implantable venous access devices in HIV-positive and HIV-negative patients. J Vasc Interv Radiol 1999; 10:71-77.
15. Ballas SK. Sickle cell disease: current clinical management. Semin Hematol 2001; 38:301-314.
16. Cantinieaux B, Boelaert JR, Meuleneire J, Kerrels V, Fondu P. Neutrophils from patients with secondary haemosiderosis contain excessive amounts of autotoxic iron. Eur J Haematol 1993; 51:161-165.
17. Tamouza R. Infectious complications in sickle cell disease are influenced by HLA Class II Alleles. Human Immunol 2002; 63:194-199.